Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients

Journal of Viral Hepatitis

Volumn 19, Issue 3, 2012, Pages 220-226

  Idilman, R ^a   Cinar, K ^a   Seven, G ^a   Bozkus, Y ^b   Elhan, A ^a   Bozdayi, M ^a   Yurdaydin, C ^a   Bahar, K ^a  

^a ANKARA UNIVERSITY   (Turkey)

^b Departments of Internal Medicine   (Turkey)

Author keywords

chronic hepatitis B; hepatitis B surface antigen quantification; hepatitis B virus; lamivudine

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; AGED; ARTICLE; DISEASE COURSE; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CIRRHOSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEROCONVERSION; TREATMENT DURATION;

ADULT; AGED; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; FIBROSIS; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; LAMIVUDINE; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84857368049     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2011.01542.x     Document Type: Article

References (43)

1. Lavanchy D,. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107. (Pubitemid 38365759)
2. Lok AS, McMahon BJ,. Chronic hepatitis B. Hepatology 2007; 45: 507-539. (Pubitemid 46374607)
3. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242.
4. Wong VW, Wong GL, Chim AM, et al. Surrogate endpoints and long-term outcome in patients with chronic hepatitis B. Clin Gastroenterol Hepatol 2009; 7: 1113-1120.
5. Lai CL, Yuen MF,. The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and endpoints. Ann Intern Med 2007; 147: 58-61.
6. McMahon BJ,. The natural history of chronic hepatitis B virus infection. Hepatology 2009; 49: S45-S55.
7. Liaw YF,. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int 2009; 29: 100-107.
8. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-686. (Pubitemid 43374518)
9. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73. (Pubitemid 43042691)
10. Brunetto MR, Moriconi F, Bonino F, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49: 1141-1150.
11. Lampertico P, Del Ninno E, Vigano M, et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 2003; 37: 756-763. (Pubitemid 36397385)
12. Marcellin P, Lau GKK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-1217. (Pubitemid 39296307)
13. McMahon BJ, Holck P, Bulkow L, Snowball M,. Serologic and clinical outcomes of 1536 Alaska natives chronically infected with hepatitis B virus. Ann Intern Med 2001; 135: 759-768. (Pubitemid 33051260)
14. Liaw YF, Sheen IS, Chen TJ, Chu CM, Pao CC,. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology 1991; 13: 627-631.
15. Lai CL, Chien R, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339: 61-68. (Pubitemid 28304879)
16. Dienstag JG, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-1263. (Pubitemid 29489740)
17. Hui JM, George J, Liddle C, et al. Changes in serum albumin during treatment of chronic hepatitis B with lamivudine: effects of response and emergence of drug resistance. Am J Gastroenterol 2002; 97: 1003-1009. (Pubitemid 34408261)
18. Liaw JF, Sung JJY, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-1531.
19. Matsumoto A, Tanaka E, Rokuhara A, et al. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: a multicenter retrospective study of 2795 patients. Hepatol Res 2005; 32: 173-184. (Pubitemid 41078655)
20. Lee HJ, Eun JR, Jang BI, Kim TN,. Prevention by lamivudine of hepatocellular carcinoma in patients with hepatitis B virus. Gut Liver 2007; 1: 151-158.
21. Eun JR, Lee HJ, Kim TN, Lee KS,. Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease. J Hepatol 2010; 53: 118-125.
22. Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 687-696. (Pubitemid 36337972)
23. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 1714-1722. (Pubitemid 37500436)
24. Manesis EK, Hadziyannis ES, Angelopoulou OP, Hadziyannis SJ,. Prediction of treatment-related HBsAg loss in HBeAg-negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir Ther 2007; 12: 73-82. (Pubitemid 46340428)
25. Reijnders JGP, Rijckborst V, Sonneveld MJ, et al. Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. J Hepatol 2011; 54: 449-454.
26. Marcellin P, Bonino F, Lau GKK, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alfa-2a. Gastroenterology 2009; 136: 2169-2179.
27. d'Ettorre G, Barbarini G, Corti F, et al. Seroconversion of HBsAg in HBeAg positive and negative patients with chronic HBV treated with entecavir: a case series. Eur Rev Med Pharmacol Sci 2010; 14: 551-554.
28. Gish RG, Chang TT, Lai CL, et al. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B. J Viral Hepat 2010; 17: 16-22.
29. Flink HJ, van Zonneveld M, Hansen BE, et al. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 2006; 101: 297-303. (Pubitemid 43381671)
30. Bozdayi M, Aslan N, Bozdayi G, et al. Molecular epidemiology of hepatitis B, C and D viruses in Turkish patients. Arch Virol 2004; 149: 2115-2129. (Pubitemid 39508954)
31. Yuen MF, Sablon E, Hui CK, et al. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001; 34: 785-791. (Pubitemid 32928004)
32. Locarnini S, Qi X, Arterburn S, et al. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB). J Hepatol 2005; 42 (Suppl. 2): 17.
33. Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbuvidine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005; 129: 528-536. (Pubitemid 41096641)
34. Yuen MF, Fong DYT, Wong DKH, et al. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology 2007; 46: 1695-1703.
35. Zoulim F, Locarnini S,. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009; 137: 1593-1608.
36. Idilman R, Kaymakoglu S, Oguz O, et al. A short-course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B. J Viral Hepat 2009; 16: 279-285.
37. Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126: 1750-1758. (Pubitemid 38736340)
38. Sung JJ, Wong ML, Bowden S, et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005; 128: 1890-1897. (Pubitemid 40824700)
39. Chan HL, Wong VW, Tse AM, et al. Serum hepatitis B surface antigen quantification can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007; 5: 1462-1468. (Pubitemid 350181604)
40. Sonneveld MJ, Rijckborst V, Boucher CAB, Hansen BE, Janssen HIA,. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e-antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010; 52: 1251-1257.
41. Thompson AJ, Nguyen T, Iser D, et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 2010; 51: 1933-1944.
42. Buster EHCJ, Hansen BE, Lau GKK, et al. Factors that predict response of patients with hepatitis B e-antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009; 137: 2002-2009.
43. Borgniet O, Parvaz P, Bouix C, et al. Clearance of serum HBsAg and anti-HBs seroconversion following antiviral therapy for chronic hepatitis B. J Med Virol 2009; 81: 1336-1342.